SCHEMBL339328

SCHEMBL339328

N=NS(N)(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14697526 0.67
SCHEMBL10478906 0.67 CA1 (0.46)
SCHEMBL3086740 0.67
SCHEMBL10478911 0.67 CA1 (0.46)
SCHEMBL3278397 0.67
Sulfamide SCHEMBL19639013 0.64
SCHEMBL41623 0.64
SCHEMBL16834201 0.64
SCHEMBL8995855 0.64
SCHEMBL15361466 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117980327-A Specific coupling of antibodies 杭州多禧生物科技有限公司 2024-05-03 CN claimed
CN-116710146-A Antibody molecule-drug conjugates and uses thereof 威特拉公司 2023-09-05 CN claimed
WO-2023138211-A1 STAR-SHAPED β-ANTIBACTERIAL GLYCOPEPTIDE, PREPARATION METHOD THEREFOR AND USE THEREOF 苏州万维生命科学技术有限公司 2023-07-27 WO claimed
CN-114828860-A Transdermal microflora preparation 霍夫曼技术有限责任公司 2022-07-29 CN claimed
US-10449247-B2 Compositions and methods for enhancing immune response AVIVAGEN INC. (CA) 2019-10-22 US claimed
CN-109689067-A GLYCAN COMPOSITIONS AND METHODS OF USE 卡莱多生物科技有限公司 2019-04-26 CN claimed
US-20190022274-A1 FORMATION OF SEMI-PERMEABLE POROUS ARTIFICIAL SCAB VEGA VILLAVICENCIO PARSIVAL (AR) 2019-01-24 US claimed
EP-2939678-B1 THIXOTROPIC FLUID FOR USE AS A CICATRIZING AGENT VEGA VILLAVICENCIO PARSIVAL (AR) 2017-04-19 EP claimed
US-20160000963-A1 FORMATION OF SEMI-PERMEABLE POROUS ARTIFICAL SCAB VEGA VILLAVICENCIO PARSIVAL (US) 2016-01-07 US claimed
EP-2273989-A1 COMBINATION THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS Interface Biologics Inc. (CA) 2011-01-19 EP claimed
EP-0792371-A4 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO INC (US) 1998-12-30 EP claimed
EP-0792371-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-09-03 EP claimed
EP-0786999-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-08-06 EP claimed
EP-0741570-A1 METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS G.D. SEARLE &amp; CO. (US) 1996-11-13 EP claimed
US-5543417-A 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent MERCK & CO., INC. (US) 1996-08-06 US claimed
WO-1996012487-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1996012817-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1995020387-A1 METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS G.D. SEARLE & CO. (US) 1995-08-03 WO claimed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed